skin medicine under trademarks including trademark of “DERMALIS”, (which will be Criterion Calculation Method Transaction size 1. Net tangible assets (NTA) Proportion of assets acquired (100%) x NTA AT

5.8 Manufacture and skincare products, cosmetics, food supplements and medicine used to treat skin diseases segment 9,708 2.2 13,124 3.2 (3,416) (26.0) total 443,248 100.0 417,617 100.0 25,631 6.1 The

has received total proceeds from the exercise of VGI-W1 warrants of THB 8,618mn1, or around 72% of maximum proceeds. The cash received was utilised for the acquisition of Kerry, while the remaining

32.6 Debt Service Coverage 904.1 4.4 103.9 4.6 Total Debt to Equity 0.2 0.4 0.2 0.4 * calculated by using earnings of current quarter to be estimated for annual earnings ** based on only cost of medicine

operations for 2nd Quarter of 2017 decreased to 71.69%, while it was 74.38% for the 2nd Quarter of 2016. These resulted from the efficiency of medicine and medical supplies cost management, introducing an

personnel to support its expansion such as Cardiac Medicine department and Opthalmology department. Selling Expenses For the 6-month periods of 2015 and 2016 , the Company and its subsidiary incurred selling

Totabl Debt to Equity 0.13 0.25 * based on only cost of medicine & medical supplies

medicine & medical supplies

53.7 Debt Service Coverage 673.5 10.1 Total Debt to Equity 0.2 0.3 * calculated by using earnings of current quarter to be estimated for annual earnings ** based on only cost of medicine & medical

capital from 135,000,000 Baht to 134,476,723.50 Baht by cancelling 1,046,553 unissued ordinary shares at the par value of Baht 0.50 each, to reserve for the exercise of warrants No.1 (DIMET-W1) on the